Tagraxofusp

Menarini Group and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize ELZONRIS® (Tagraxofusp) in Japan

Retrieved on: 
Monday, March 29, 2021
Branches of biology, Clinical medicine, Medicine, Blastic plasmacytoid dendritic cell neoplasm, Tagraxofusp, Plasmacytoid dendritic cell, Dendritic cell, Interleukin-3 receptor

ELZONRIS (tagraxofusp) is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in both the United States and Europe.

Key Points: 
  • ELZONRIS (tagraxofusp) is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in both the United States and Europe.
  • "Patients with BPDCN have limited treatment options and we are excited to be collaborating closely with Nippon Shinyaku to make ELZONRIS (tagraxofusp) available to patients in Japan."
  • ELZONRIS(tagraxofusp) is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  • ELZONRIS should be administered under the supervision of a physician experienced in the use of anti-cancer agents.

Menarini Group and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize ELZONRIS® (Tagraxofusp) in Japan

Retrieved on: 
Monday, March 29, 2021
Branches of biology, Clinical medicine, Medicine, Blastic plasmacytoid dendritic cell neoplasm, Tagraxofusp, Plasmacytoid dendritic cell, Dendritic cell

Elzonris was originally developed by Stemline Therapeutics, now part of the Menarini Group.

Key Points: 
  • Elzonris was originally developed by Stemline Therapeutics, now part of the Menarini Group.
  • "Patients with BPDCN have limited treatment options and we are excited to be collaborating closely with Nippon Shinyaku to make ELZONRIS (tagraxofusp) available to patients in Japan."
  • "Through this development and commercial partnership, we look forward to advancing ELZONRIS as a potential new treatment option for patients suffering from BPDCN."
  • ELZONRIS(tagraxofusp) is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Retrieved on: 
Thursday, January 21, 2021
Branches of biology, Medical specialties, Blastic plasmacytoid dendritic cell neoplasm, Plasmacytoid dendritic cell, Dendritic cell, Tagraxofusp, Neural cell adhesion molecule, Lymphoma, Natural killer cell, Myeloid leukemia, Tumors of the hematopoietic and lymphoid tissues

ELZONRIS(tagraxofusp) is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Key Points: 
  • ELZONRIS(tagraxofusp) is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  • ELZONRIS should be administered under the supervision of a physician experienced in the use of anti-cancer agents.
  • The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor.
  • The World Health Organization (WHO) termed this disease "BPDCN" in 2008; previous names included blastic NK cell lymphoma and agranular CD4+/CD56+ hematodermic neoplasm.

CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Retrieved on: 
Friday, November 13, 2020
Branches of biology, Medical specialties, Blastic plasmacytoid dendritic cell neoplasm, Lymphocytes, Plasmacytoid dendritic cell, Dendritic cell, Tagraxofusp, Neural cell adhesion molecule, Lymphoma, Natural killer cell

The CHMP opinion will now be reviewed by the European Commission, which has the authority to grant marketing authorization for human medicines throughout the European Union (EU).

Key Points: 
  • The CHMP opinion will now be reviewed by the European Commission, which has the authority to grant marketing authorization for human medicines throughout the European Union (EU).
  • For this reason, we are particularly thrilled to be one step closer to making ELZONRIS available for BPDCN patients".
  • The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor.
  • The World Health Organization (WHO) termed this disease "BPDCN" in 2008; previous names included blastic NK cell lymphoma and agranular CD4+/CD56+ hematodermic neoplasm.

CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Retrieved on: 
Friday, November 13, 2020
Branches of biology, Medical specialties, Blastic plasmacytoid dendritic cell neoplasm, Lymphocytes, Plasmacytoid dendritic cell, Dendritic cell, Tagraxofusp, Neural cell adhesion molecule, Lymphoma, Natural killer cell

The CHMP opinion will now be reviewed by the European Commission, which has the authority to grant marketing authorization for human medicines throughout the European Union (EU).

Key Points: 
  • The CHMP opinion will now be reviewed by the European Commission, which has the authority to grant marketing authorization for human medicines throughout the European Union (EU).
  • For this reason, we are particularly thrilled to be one step closer to making ELZONRIS available for BPDCN patients".
  • The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor.
  • The World Health Organization (WHO) termed this disease "BPDCN" in 2008; previous names included blastic NK cell lymphoma and agranular CD4+/CD56+ hematodermic neoplasm.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - Epidemiology Forecast - 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 21, 2020
Biotechnology, Health, Oncology, Branches of biology, Medical specialties, Immunology, Blastic plasmacytoid dendritic cell neoplasm, Dendritic cell, Plasmacytoid dendritic cell, Medicine, PDC, Myeloid leukemia, Tagraxofusp

The "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Blastic plasmacytoid dendritic cell neoplasm (BPDCN) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Epidemiology Report and Model provide an overview of the risk factors and global trends of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight about the historical and forecasted patient pool of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
    The report provides the segmentation of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology by Incident Cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 7MM.
  • The report provides the segmentation of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology by gender-specific Incident Cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 7MM.
  • The report provides the segmentation of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology by age-specific Prevalent Cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 7MM.